K
Karyopharm Therapeutics D
D
KPTI
0.64000
USD
-0.00
(-0.67%)
مفتوح الان
حجم التداول
4,292
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
80,762,076
الأخبار
المقالات
العنوان: Karyopharm Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuselarge B-cell lymphoma. The company derives its revenue from United States.